Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-Label Study of the Safety of HPN-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)

NCT00947297 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00947297
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00947297 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-Label Study of the Safety of HPN-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2009
Completion date
November 30, 2011
Enrollment
60 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

urea cycle disorders